SAB Biotherapeutics Warrant
SABSW
14 hedge funds and large institutions have $289K invested in SAB Biotherapeutics Warrant in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
8% more funds holding
Funds holding: 13 → 14 (+1)
0.08% more ownership
Funds ownership: 3.95% → 4.03% (+0.08%)
23% less capital invested
Capital invested by funds: $376K → $289K (-$87.1K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$1.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$15 |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $237K | – | – | – |
|
|
SCM
2
Shaolin Capital Management
Miami,
Florida
| $18K | – | – | – |
|
3
Balyasny Asset Management
Chicago,
Illinois
| $15.8K | – | – | – |
|
|
YCM
4
Yakira Capital Management
Westport,
Connecticut
| $6.12K | – | – | – |
|
5
Morgan Stanley
New York
| $5.36K | – | – | – |
|
|
EPM
6
Equitec Proprietary Markets
Chicago,
Illinois
| $1.62K | – | – | – |
|
|
MC
7
Meteora Capital
Boca Raton,
Florida
| $1.28K | +$1.99K | +35,446 | New |
|
|
FTUS
8
Flow Traders U.S.
New York
| $1K | -$4 | -75 | -0.5% |
|
9
Walleye Capital
New York
| $837 | – | – | – |
|
|
10
Jane Street
New York
| $600 | -$15 | -260 | -2% |
|
11
Walleye Trading
New York
| $558 | – | – | – |
|
|
WAM
12
Wolverine Asset Management
Chicago,
Illinois
| $460 | – | – | – |
|
|
NA
13
NewEdge Advisors
New Orleans,
Louisiana
| $39 | – | – | – |
|
SABSW Hedge Fund Activity: Q1 2023 in Review
14 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2023, worth a combined $289K — down 23% from $376K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SABSW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Meteora Capital, opening a new position worth an estimated $1.99K. The largest seller was Jane Street, cutting an estimated $15.
- 14 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2023, up from 13 in Q4 2022.
- Funds reported $289K of SAB Biotherapeutics Warrant stock for Q1 2023, down 23% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest SAB Biotherapeutics Warrant buyer in Q1 2023 was Meteora Capital, an estimated $1.99K added.
- The largest SAB Biotherapeutics Warrant seller in Q1 2023 was Jane Street, an estimated $15 sold.
Based on aggregated 13F filings for Q1 2023.